Replies to post #398888 on Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

I do not disagree with you. This is what Basilea says:
"As the rise of antimicrobial resistance has been
recognized as a global health concern, there
have been significant investments into the dis-
covery of new treatment modalities. However,
research institutes and smaller companies of-
ten lack the resources and know-how to profile
and develop early-stage drug candidates in a
way that allows for successful commercial posi-
tioning. Bigger pharmaceutical corporations are
more focused on commercializing anti-infective
drugs once clinical development has been com-
pleted. We are convinced that Basilea is uniquely
positioned to fill this void in the value chain in
an area with increasing medical need."
https://www.basilea.com/investor-center#c161

Also agree with Hazelhurst on expected Merck interest in Brilacidin.